NCT01272141

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

Phase II Trial of Lapatinib in Combination With Everolimus in Triple Negative Metastatic or Locally Advanced Breast Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Emory University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with everolimus, an agent that targets a protein in the cancer cell, called mammalian target of rapamycin (mTOR) is effective in metastatic triple negative breast cancers that are no longer controlled by standard chemotherapy.

Conditions

• Breast Neoplasms
• Breast Cancer
• Cancer of the Breast

Interventions

Type	Name	Description
DRUG	Lapatinib and Everolimus	Lapatinib: 1250 mg by mouth daily Everolimus: 5mg by mouth daily

Timeline

• Start date: 2010-12-01
• Primary completion: 2013-01-01
• Completion: 2014-01-01
• First posted: 2011-01-07
• Last updated: 2014-09-22
• Results posted: 2014-09-10

Locations

3 sites across 1 country: United States